Myriad Genetics (MYGN) Tops Q3 EPS by 8c

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $173.1 million versus the consensus estimate of $156.2 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Premarket movers: Quest, Labcorp hit by CMS cuts
• Amrize Ltd (AMRZ) PT Lowered to $42 at UBS on Lower Earnings Estimates